36.10

1.11% 0.395

After Hours: 36.00 -0.10 -0.28%

Tg Therapeutics Inc (TGTX)

Overview News Price History Option Chain Financials Why TGTX Down? Discussions Forecast Stock Split

Tg Therapeutics Inc stock is traded at $36.10, with a volume of 2.47M. It is up +1.11% in the last 24 hours and up +7.66% over the past month. TG Therapeutics Inc is a fully integrated, commercial-stage biotechnology company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. In addition to a research pipeline, it has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. Its pipeline includes UBLITUXIMAB, SUB-Q UBLITUXIMAB, and AZER-CEL. Geographically, it generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from the international market.

Previous Close:

$35.70

Open:

$35.905

24h Volume:

2.47M

Relative Volume:

1.31

Market Cap:

$5.53B

Revenue:

$616.29M

Net Income/Loss:

$447.18M

P/E Ratio:

13.00

EPS:

2.7771

Net Cash Flow:

$-24.99M

1W Performance:

+4.40%

1M Performance:

+7.66%

6M Performance:

+6.05%

1Y Performance:

-4.19%

1-Day Range:

$34.87

$36.28

1-Week Range:

$33.23

$36.28

52-Week Range:

$25.28

$40.99

Tg Therapeutics Inc Stock (TGTX) Company Profile

Name

Tg Therapeutics Inc

Sector

Healthcare (1106)

Industry

Biotechnology (615)

Phone

(212) 554-4484

Address

2 GANSEVOORT STREET, 9TH FLOOR, NEW YORK, NY

Employee

399

Twitter

@TGTherapeutics

Next Earnings Date

2026-05-06

Latest SEC Filings

TGTX's Discussions on Twitter

Compare TGTX vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
TGTX Tg Therapeutics Inc	36.10	5.47B	616.29M	447.18M	-24.99M	2.7771
VRTX Vertex Pharmaceuticals Inc	424.36	109.34B	12.32B	4.34B	3.19B	16.86
REGN Regeneron Pharmaceuticals Inc	702.27	74.35B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	794.70	50.44B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	301.11	39.78B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	297.49	33.02B	5.36B	287.73M	924.18M	2.5229

Tg Therapeutics Inc Stock (TGTX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Oct-06-25	Resumed	H.C. Wainwright	Buy
Jul-10-25	Resumed	Goldman	Neutral
Oct-29-24	Initiated	TD Cowen	Buy
Aug-02-23	Upgrade	Goldman	Sell → Neutral
Jun-26-23	Resumed	Jefferies	Buy
May-20-22	Initiated	BofA Securities	Underperform
Feb-23-22	Reiterated	B. Riley Securities	Buy
Nov-15-21	Downgrade	Goldman	Neutral → Sell
Apr-20-21	Initiated	Goldman	Neutral
Apr-19-21	Reiterated	H.C. Wainwright	Buy
Sep-01-20	Initiated	JP Morgan	Overweight
Aug-11-20	Reiterated	H.C. Wainwright	Buy
Jun-05-20	Initiated	Evercore ISI	Outperform
Jan-17-20	Reiterated	H.C. Wainwright	Buy
Nov-27-19	Resumed	B. Riley FBR	Buy
Feb-06-19	Resumed	Jefferies	Buy
Sep-25-18	Downgrade	Raymond James	Strong Buy → Outperform
Mar-09-18	Reiterated	B. Riley FBR, Inc.	Buy
Dec-01-17	Resumed	B. Riley FBR, Inc.	Buy
Nov-14-17	Resumed	H.C. Wainwright	Buy
Apr-25-17	Initiated	Jefferies	Buy
Mar-06-17	Reiterated	FBR & Co.	Outperform
Oct-06-16	Resumed	Brean Capital	Buy
May-27-16	Initiated	SunTrust	Buy
Dec-01-15	Initiated	FBR Capital	Outperform
Sep-09-15	Initiated	Raymond James	Strong Buy
Aug-12-15	Resumed	H.C. Wainwright	Buy
Jun-19-15	Reiterated	Brean Capital	Buy
Dec-11-14	Reiterated	ROTH Capital	Buy
Dec-10-14	Reiterated	ROTH Capital	Buy

View All

Tg Therapeutics Inc Stock (TGTX) Latest News

01:12 AM

MSN Money - MSN

01:12 AM

12:41 PM

TG Therapeutics faces earnings test on margin expansion - Investing.com

12:41 PM

07:19 AM

Precision BioSciences (DTIL) posts Q1 2026 results and advances HBV and DMD gene editing - Stock Titan

07:19 AM

May 04, 2026

Trading the Move, Not the Narrative: (TGTX) Edition - Stock Traders Daily

May 04, 2026

TG Therapeutics Jumps 5.1% Amid Sector-Wide Rally - AlphaStreet

May 04, 2026

May 03, 2026

Assessing TG Therapeutics (TGTX) Valuation As BRIUMVI Subcutaneous Launch Potential Draws Focus - Sahm

May 03, 2026

May 02, 2026

CapEx per share of TG Therapeutics, Inc. – LSX:A1JXW7 - TradingView

May 02, 2026

May 01, 2026

TG Therapeutics to Host Conference Call on First Quarter 2026 Financial Results and Business Update - Moomoo

May 01, 2026

TGTX Stock Price, Quote & Chart | TG THERAPEUTICS INC (NASDAQ:TGTX) - ChartMill

May 01, 2026

Apr 30, 2026

Executive pay, auditor and board up for votes at TG Therapeutics (TGTX) 2026 meeting - Stock Titan

Apr 30, 2026

Pictet Asset Management Holding SA Trims Stock Position in TG Therapeutics, Inc. $TGTX - MarketBeat

Apr 30, 2026

TG Therapeutics, Inc. (NASDAQ:TGTX) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat

Apr 30, 2026

Apr 29, 2026

Vanguard Portfolio Management discloses 5.26% stake in TG Therapeutics (NASDAQ: TGTX) - Stock Titan

Apr 29, 2026

TGTX Technical Analysis | Trend, Signals & Chart Patterns | TG THERAPEUTICS INC (NASDAQ:TGTX) - ChartMill

Apr 29, 2026

Apr 28, 2026